Casey Rand

Mr. Casey Rand

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SBSarah Barclay
Sarah Barclay
CRCasey Rand
Casey Rand
LBLauren A. Borch
Lauren A. Borch
LNLisa Nguyen
Lisa Nguyen
PGPaul A. Gray
Paul A. Gray
NBN. Torben Bech-Hansen
N. Torben Bech-Hansen
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) is thought to be a genetic disease caused by de novo mutations, though causative mutations have yet to be identified. We searched for de novo coding mutations among a carefully-diagnosed and clinically homogeneous cohort of 35 ROHHAD patients. We sequenced the exomes of seven ROHHAD trios, plus tumours from four of these patients and the unaffected monozygotic (MZ) twin of one (discovery cohort), to identify constitutional and somatic de novo sequence variants. We further analyzed this exome data to search for candidate genes under autosomal dominant and recessive models, and to identify structural variations. Candidate genes were tested by exome or Sanger sequencing in a replication cohort of 28 ROHHAD singletons. The analysis of the trio-based exomes found 13 de novo variants. However, no two patients had de novo variants in the same gene, and additional patient exomes and mutation analysis in the replication cohort did not provide strong genetic evidence to implicate any of these sequence variants in ROHHAD. Somatic comparisons revealed no coding differences between any blood and tumour samples, or between the two discordant MZ twins. Neither autosomal dominant nor recessive analysis yielded candidate genes for ROHHAD, and we did not identify any potentially causative structural variations. Clinical exome sequencing is highly unlikely to be a useful diagnostic test in patients with true ROHHAD. As ROHHAD has a high risk for fatality if not properly managed, it remains imperative to expand the search for non-exomic genetic risk factors, as well as to investigate other possible mechanisms of disease. In so doing, we will be able to confirm objectively the ROHHAD diagnosis and to contribute to our understanding of obesity, respiratory control, hypothalamic function, and autonomic regulation.

20 July 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SBSarah Barclay
Sarah Barclay
CRCasey Rand
Casey Rand
LNLisa Nguyen
Lisa Nguyen
RWRichard J. A. Wilson
Richard J. A. Wilson
RWRachel Wevrick
Rachel Wevrick
DWDebra E. Weese-Mayer
Debra E. Weese-Mayer
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a very rare and potentially fatal pediatric disorder, the cause of which is presently unknown. ROHHAD is often compared to Prader-Willi syndrome (PWS) because both share childhood obesity as one of their most prominent and recognizable signs, and because other symptoms such as hypoventilation and autonomic dysfunction are seen in both. These phenotypic similarities suggest they might be etiologically related conditions. We performed an in-depth clinical comparison of the phenotypes of ROHHAD and PWS and used NGS and Sanger sequencing to analyze the coding regions of genes in the PWS region among seven ROHHAD probands. Detailed clinical comparison of ROHHAD and PWS patients revealed many important differences between the phenotypes. In particular, we highlight the fact that the areas of apparent overlap (childhood-onset obesity, hypoventilation, autonomic dysfunction) actually differ in fundamental ways, including different forms and severity of hypoventilation, different rates of obesity onset, and different manifestations of autonomic dysfunction. We did not detect any disease-causing mutations within PWS candidate genes in ROHHAD probands. ROHHAD and PWS are clinically distinct conditions, and do not share a genetic etiology. Our detailed clinical comparison and genetic analyses should assist physicians in timely distinction between the two disorders in obese children. Of particular importance, ROHHAD patients will have had a normal and healthy first year of life; something that is never seen in infants with PWS.

1 January 2016 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
SBSarah Barclay
Sarah Barclay
CRCasey Rand
Casey Rand
PGPaul A. Gray
Paul A. Gray
WGWilliam T. Gibson
William T. Gibson
RWRichard J.A. Wilson
Richard J.A. Wilson
DWDebra E. Weese-Mayer
Debra E. Weese-Mayer

7 July 2006 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CRCasey Rand
Casey Rand
DWDebra E. Weese‐Mayer
Debra E. Weese‐Mayer
LZLili Zhou
Lili Zhou
BMBrion S. Maher
Brion S. Maher
MCMargaret E. Cooper
Margaret E. Cooper
EBElizabeth M. Berry‐Kravis
Elizabeth M. Berry‐Kravis

28 March 2025 in Pediatric Pulmonology
Verified
Journal Article
Open access
BDBenjamin Dudoignon
Benjamin Dudoignon
PBPlamen Bokov
Plamen Bokov
FBFatima Benterki
Fatima Benterki
NCNathalie Couque
Nathalie Couque
CRCasey Rand
Casey Rand
CDChristophe Delclaux
Christophe Delclaux
Rationale: Congenital central hypoventilation syndrome (CCHS) is a rare disorder characterized by alveolar hypoventilation and variable autonomic nervous system (ANS) dysfunction (ANSD) due to mutations in PHOX2B, a gene crucial for ANS neural crest lineage differentiation.Objectives and Methods: Our prospective study aims were twofold: to (1) assess the relationships between the subjective Composite Autonomic Symptom Score (COMPASS)‐31 and objective indices of ANSD obtained from heart rate variability analyses, ambulatory blood pressure (BP) monitoring, and CO2 chemosensitivities and (2) describe the organ system ANSD, its relationship to PHOX2B genotype, and its consequences on quality of life (PedsQL) in children with CCHS.Results: Thirty‐two PHOX2B mutation‐confirmed subjects (median [range] age 9.2 years (4.4; 18.0), 15 girls) were enrolled. COMPASS‐31 was assessed in 32 matched (sex and age, range: 4.3; 18.9 years) healthy controls. As compared to healthy controls, children with CCHS had increased vasomotor (p = 0.001), secretomotor (p = 0.021), gastrointestinal (p = 0.002) and pupillomotor (p = 0.028) scores and decreased orthostatic intolerance scores (p = 0.050). There was no difference in overall COMPASS‐31 score between CCHS and controls (p = 0.083). However, in CCHS, overall COMPASS‐31 scores correlated with high frequencies (HF) normalized (cardiac parasympathetic modulation: R = −0.53; p = 0.002), low frequencies (LF)/HF ratio (R = 0.56; p< 0.001), and both systolic and diastolic nighttime BP dipping (R = 0.45, p = 0.012 and R = 0.40, p = 0.028, respectively). No significant relationships between COMPASS‐31 scores and chemosensitivity testing, PedsQL scores, or PHOX2B genotype were identified.Conclusions: COMPASS‐31 identified some aspects of CCHS‐related ANSD, and scores correlate with objective ANS function measures, supporting the potential utility of COMPASS‐31 in CCHS.

21 March 2025 in Pediatric Pulmonology
Verified
Journal Article
Open access
CRCasey Rand
Casey Rand
JPJulien Pelissou
Julien Pelissou
NKNarayanan Krishnamurthi
Narayanan Krishnamurthi
XCXenia Proton de la Chapelle
Xenia Proton de la Chapelle
MSMartin Samuels
Martin Samuels
DWDebra E. Weese‐Mayer
Debra E. Weese‐Mayer
Background: Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by autonomic dysregulation and abnormal control of breathing, necessitating lifelong artificial ventilation. The impact of CCHS on patient quality of life (QoL) and caregiver burden remains unquantified.Methods: A cross‐sectional study of QoL in CCHS patients (≥ 12 years; WHOQOL–BREF) and burden in CCHS caregivers (Zarit Burden Interview) was conducted. Participants were recruited from CCHS support organizations. Participant age group, sex, primary language, and country of residence were collected.Results: Two hundred seventy‐one individuals (78 CCHS, 193 caregivers) from 15 countries participated. CCHS patients reported significantly reduced physical, psychological, and social relationships domain scores compared to healthy controls (p < 0.01), yet > 70% reported good overall QoL. Over half reported moderate or worse impact on QoL items including medical treatment dependence and cognitive function. Young CCHS patients (< 25 years) reported better overall QoL and general health than those ≥ 25 years. CCHS caregiver burden was increased compared to that reported in other chronic diseases, with > 50% reporting frequent caregiving‐induced stress. Caregivers who reported financial issues also reported higher total burden (p < 0.05).Conclusions: CCHS QoL scores are depressed compared to healthy individuals. This study identified specific domains of QoL and caregiver burden most impacted by CCHS, revealed a relationship between age and QoL in CCHS, and finances and burden in caregivers. Results offer targets for future interventions to enhance QoL in CCHS and reduce caregiver burden. Further work is needed to elucidate the relationship between CCHS impact and disease‐ and treatment‐specific factors.